Ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections

Draft guidance (PDF version) (PDF 299 KB)

Committee meeting

Minutes (MSWord 32 KB)

Agenda : Committee slides (PowerPoint 1.73 MB)

Agenda : Pfizer evidence submission (MSWord 2.37 MB)

Agenda : Pfizer submission - Global Atlas Surveillance data 2014-2020 (MSWord 17 KB)

Agenda : Pfizer submission - Paper reference table (MSWord 21 KB)

Agenda : Patient group submission - Anthony Nolan (MSWord 66 KB)

Agenda : Patient group submission - Antibiotic Research UK (MSWord 70 KB)

Agenda : Professional group submission - British Infection Association (MSWord 62 KB)

Agenda : Professional group submission - British Society for Antimicrobial Chemotherapy-Royal College of Pathologists (MSWord 70 KB)

Agenda : Professional group submission - Intensive Care Society (MSWord 72 KB)

Agenda : Professional group submission - UK Cystic Fibrosis Medical Association (MSWord 64 KB)

Agenda : Professional group submission - UK Clinical Pharmacy Association – Infection Committee (MSWord 62 KB)

Agenda : Clinical expert Andrew Seaton - statement (MSWord 69 KB)

Agenda : Clinical expert Andrew Seaton - additional information (MSWord 70 KB)

Agenda : Clinical expert Nick Brown - statement (MSWord 70 KB)

Agenda : Clinical expert Marisa Lanzman - statement (MSWord 61 KB)

Agenda : Patient expert Nicola Andrews - statement (MSWord 63 KB)

Agenda : NHS commissioning expert - statement (MSWord 59 KB)

Agenda : Assessment report prepared by EEPRU (MSWord 5.61 MB)

Agenda : Comments on the assessment report Pfizer from (MSWord 838 KB)

Agenda : Comments on the assessment report from clinical expert - Andrew Seaton (MSWord 34 KB)

Agenda : Comments on the assessment report from Antibiotic Research UK (MSWord 344 KB)

Agenda : Comments on the assessment report from British Infection Association (MSWord 36 KB)

Agenda : Comments on the assessment report from British Society for Antimicrobial Chemotherapy-Royal College of Pathologists (MSWord 36 KB)

Agenda : Comments on the assessment report from Intensive Care Society (MSWord 34 KB)

Agenda : Comments on the assessment report from NHS England-NHS Improvement (MSWord 35 KB)

Agenda : Comments on the assessment report from Merck Sharp & Dohme (MSWord 37 KB)

Agenda : Comments on the assessment report from Shionogi (MSWord 263 KB)

Agenda : Comments on the assessment report from Shionogi – additional response to AG model (MSWord 79 KB)

Agenda : Comments on the assessment report from Advisory Committee on Antimicrobial Prescribing, Resistance and Healthcare Associated Infections (MSWord 36 KB)

Agenda : EEPRU’s response to consultee and commentator comments on their assessment report (MSWord 33 KB)

Agenda : Additional analyses - addendum 1 (MSWord 327 KB)

Agenda : Additional analyses - addendum 2 (MSWord 528 KB)

Agenda : Pre-meeting briefing (PowerPoint 3.95 MB)

Agenda : Key issues for committee discussion (MSWord 53 KB)

Draft scope (pdf version) (PDF 203 KB)

Supporting documentation : Draft stakeholder list (PDF 147 KB)

Invitation to participate

Equality impact assessment (MSWord 20 KB)

Final protocol (MSWord 385 KB)

Final protocol Addendum: updated PICO tables (MSWord 22 KB)

Final scope (MSWord 40 KB)

Stakeholder list : Final (MSWord 23 KB)

NICE’s response to comments on draft scope (MSWord 95 KB)

Supporting documentation : Evaluation framework (PDF 204 KB)

Supporting documentation : Antimicrobials evaluation committee: membership (MSWord 44 KB)